
Opinion|Videos|May 29, 2024
Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting
Ke Ning, MD, describes similarities and differences when implementing bispecific antibodies and CAR T-cell therapy for patients with relapsed or remitting multiple myeloma in the community oncology setting.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Influenza Hospitalizations in Children Reveal Significant Non-respiratory Complications
2
Weight Loss Drugs On the Horizon: What Pharmacists Should Know
3
Kratom Controversies: Exploring Use and Regulation
4
FDA Approves Aflibercept Injection to Treat Patients With Macular Edema Following RVO
5

























































































































































































































